- About this Journal
- Abstracting and Indexing
- Aims and Scope
- Annual Issues
- Article Processing Charges
- Articles in Press
- Author Guidelines
- Bibliographic Information
- Citations to this Journal
- Contact Information
- Editorial Board
- Editorial Workflow
- Free eTOC Alerts
- Publication Ethics
- Submit a Manuscript
- Subscription Information
- Table of Contents
The Scientific World Journal
Volume 2013 (2013), Article ID 804505, 5 pages
RNA Editing and Drug Discovery for Cancer Therapy
1Department of Pharmacy, Kaohsiung Medical University Hospital, Kaohsiung Medical University, Kaohsiung 807, Taiwan
2Graduate Institute of Natural Products, College of Pharmacy, Kaohsiung Medical University, Kaohsiung 807, Taiwan
3Department of Biomedical Science and Environmental Biology, Kaohsiung Medical University, Kaohsiung 807, Taiwan
4Department of Radiation Oncology, Faculty of Medicine, College of Medicine, Kaohsiung Medical University, Kaohsiung 807, Taiwan
5Department of Radiation Oncology, Kaohsiung Medical University Hospital, Kaohsiung 807, Taiwan
6Department of Electronic Engineering, National Kaohsiung University of Applied Sciences, Kaohsiung 807, Taiwan
7Department of Biotechnology, Kaohsiung Medical University, Kaohsiung 807, Taiwan
8Center for Resources, Research and Development, Kaohsiung Medical University, Kaohsiung 807, Taiwan
9Cancer Center, Kaohsiung Medical University Hospital, Kaohsiung Medical University, Kaohsiung 807, Taiwan
Received 4 March 2013; Accepted 8 April 2013
Academic Editors: Y. Kumazawa and H. Nakagami
Copyright © 2013 Wei-Hsuan Huang et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
RNA editing is vital to provide the RNA and protein complexity to regulate the gene expression. Correct RNA editing maintains the cell function and organism development. Imbalance of the RNA editing machinery may lead to diseases and cancers. Recently, RNA editing has been recognized as a target for drug discovery although few studies targeting RNA editing for disease and cancer therapy were reported in the field of natural products. Therefore, RNA editing may be a potential target for therapeutic natural products. In this review, we provide a literature overview of the biological functions of RNA editing on gene expression, diseases, cancers, and drugs. The bioinformatics resources of RNA editing were also summarized.
RNA editing is the change of nucleotide sequence of RNA transcripts relative to that of the encoding DNA . RNA editing can enhance the RNA and protein diversity . Although five types of RNA editing have been discovered , the adenosine-to-inosine (A-to-I) editing is the most common type in higher eukaryotes [4–6]. The A-to-I editing may lead to changes in amino acid type and alternative splicing , thereby increasing the complexity of gene expression .
2. RNA Editing and Gene Expression
The A-to-I editing is an enzymatic process mediated by proteins of the family of adenosine deaminase acting on RNA (ADAR). Two types of A-to-I RNA editing such as site selective and hyper-editing have been summarized . The site selective way usually converses one or a few A-to-I sites but the hyperediting way causes adenine deamination of long stretches of double-strand RNA . Accordingly, the A-to-I RNA editing contributes a global posttranscriptional modification to the transcriptome diversity [10, 11]. A-to-I RNA editing is a common event that can lead to amino acid changes in translated exons and RNA folding or may edit in noncoding exons or introns [12, 13]. Additional gene products and functions are further generated than the original encoded genes to improve the complexity of gene expression.
RNA editing is essential in many organisms. Correct RNA editing is important in organism’s development . For example, RNA editing deficiency may display the deleterious phenotypes in plant and in mammals. For example, RNA editing mutant was reported with strong defects in organelle development  and with pollen abortion in male sterility . A RNA editing deficiency of glutamate receptor subunit GluR2 was reported in motor neurons of amyotrophic lateral sclerosis [16, 17]. The deficiency or misregulation of RNA editing may result in the development of diseases and cancers  as described later.
3. RNA Editing and Diseases
Since the RNA editing is essential in regulating gene expression of organisms, imbalance of RNA editing may lead to dysfunction of some proteins involved in normal physiology such as neural and immune functions. A large number of nervous system targets such as neurotransmitter receptors and ion channels [18, 19] undergo A-to-I RNA editing by ADARs . For example, the RNA editing of serotonin (5-hydroxytryptamine (5-HT)) 2C receptor (HTR2CR) was altered in a depression animal model and antidepressants commonly reduced its RNA editing efficiency [21, 22]. Furthermore, the ADAR-mediated RNA editing in nervous system tissues may occur in both coding and noncoding transcriptomes [5, 13, 23, 24]. Particularly in the nervous system, editing in non-coding regions such as microRNA and 3′ untranslated regions (UTR) of mRNAs is more frequent than in coding regions [4, 23]. Therefore, correct and regulated RNA editing is important for marinating functional nervous system and avoiding neurological diseases [8, 25].
ADARs can regulate the innate immune system by editing the RNA transcripts of immune-related genes . ADAR (ADAR1) may be involved in regulating the RNA editing and the replication of hepatitis delta virus (HDV). For example, the two forms of ADAR1 (ADAR1-S and ADAR1-L) are involved in HDV editing, where the ADAR1-S functions in unstimulated cells and ADAR1-L functions in IFN-alpha-stimulated cells . RNA editing exhibits interactions between the host ADAR1, and structural motifs in the HDV RNA may play important roles in the HDV replication cycle .
4. RNA Editing and Cancers
The regulation of ADAR was found to depend on the differentiation status of pluripotent human embryonic stem cells , suggesting that A-to-I RNA editing is involved in human embryogenesis. Interfering the regulation of differentiation and apoptosis may promote carcinogenesis . RNA regulation can modulate the expression of oncogenes or tumor suppressor genes . A-to-I editing is responsible for structure change and base pairing features of the RNA molecule  and is involved in cell differentiation . Accordingly, A-to-I RNA editing may contribute to cancer development and progression [34, 35].
For example, ADAR1 was downregulated when growth rates of HeLa-cell-derived tumors in xenograft model were inhibited . ADAR1 deletion leads to regression of established chronic myelogenous leukemia in mice . ADARB2 (ADAR3) mRNA was decreased in glioblastoma multiforme , suggesting that reduced A-to-I editing is involved in brain carcinogenesis. However, downregulation of ADARB1 (ADAR2) inhibited cellular proliferation of pediatric astrocytoma  and glioblastoma . Additionally, RNA editing may not be involved in the carcinogenesis of urinary bladder cancer .
Recently, some cancer-related RNA editing targets were discovered such as antizyme inhibitor 1 (AZIN1) and glioma-associated oncogene 1 (GLI1). A-to-I RNA editing of AZIN1 is increased in hepatocellular carcinoma . RNA editing of GLI1 transcription factor involved in Hedgehog signaling is decreased in basal cell carcinoma tumor . Therefore, the imbalance in expression of ADAR enzymes is highly correlated with cancer development and progression [52, 53].
5. RNA Editing and Drugs
mRNA transcript diversity such as RNA editing has profound impact on drug discovery [2, 54]. In addition to main gene products, isoforms generated by RNA editing may provide additional drug targets that have preferential physiological effects. Accordingly, transcript diversity creates potentially new opportunities for drug design, development, and therapy .
RNA editing has been suggested to be a therapeutic target for CNS disorders . For example, RNA editing of the 5HT2C receptor may affect cell signaling, drug response, and brain function . A-to-I RNA editing can also modulate the drug response of some channels, such as Kv1.1 channel [2, 57]. Therefore, RNA editing of these receptor and channels may change their protein functions and become a target for disease therapy .
Recently, some drugs for inhibiting RNA editing enzymes were discovered. For example, novel inhibitors of Trypanosoma brucei RNA editing ligase 1 were reported to be potential therapeutic drugs [58, 59].
6. RNA Editing and Bioinformatics Resources
Although there is a high chance of finding natural products that could target the RNA editing enzymes or lead to the RNA editing of some target genes, such investigations are still rare. It is possible that certain natural products have the potential to be the inhibitors or modulators for RNA editing and may have impacts on the disease and cancer therapy. Therefore, we collected the bioinformatics resources of RNA editing (Table 1) to help the researchers of natural products to investigate the effect of natural products on RNA editing.
In brief, dbRES  contains known RNA editing sites curated from the literature and GenBank. DARNED [37, 38] contains region-, gene-, and sequence-based inputs for RNA editing data retrieval from human and model organisms. miR-EdiTar  contains predicted miRNA binding sites that could be modified by A-to-I-editing, as well as A-to-I editing-induced miRNA binding sites. Both ExpEdit  and RNA-eXpress  are the annotation tools of RNA editing prediction for RNA-Seq data. For organellar RNA editing resources, GOBASE , REDIdb , and PREPACT 2.0  contain the interface for RNA editing data of mitochondrion- and chloroplast-encoded sequences. Some bioinformatics resources of RNA editing in plants [60–63] were not included in Table 1 because they have little relationships to drug discovery.
In the future, we expect that RNA editing studies related to natural products may be accumulating. We hope that this concept can inspire the scientific idea to connect the fields of RNA editing research and natural products for drug discovery in cancer therapy.
This study was supported by a grant from the Kaohsiung Medical University Hospital-(KMUH99-9 M36), the Department of Health, Executive Yuan, Republic of China (DOH102-TD-C-111-002), the Kaohsiung Medical University Research Foundation (KMUER001 and KMUCOP-102-05), and the National Sun Yat-Sen University-KMU Joint Research Project (no. NSYSU-KMU 102-034).
- M. W. Gray, “Evolutionary origin of RNA editing,” Biochemistry, vol. 51, no. 26, pp. 5235–5242, 2012.
- N. Decher, M. F. Netter, and A. K. Streit, “Putative impact of RNA editing on drug discovery,” Chemical Biology & Drug Design, vol. 81, no. 1, pp. 13–21, 2013.
- W. Tang, Y. Fei, and M. Page, “Biological significance of RNA editing in cells,” Molecular Biotechnology, vol. 52, no. 1, pp. 91–100, 2012.
- B. Zinshteyn and K. Nishikura, “Adenosine-to-inosine RNA editing,” Wiley Interdisciplinary Reviews, vol. 1, no. 2, pp. 202–209, 2009.
- K. Nishikura, “Functions and regulation of RNA editing by ADAR deaminases,” Annual Review of Biochemistry, vol. 79, pp. 321–349, 2010.
- C. N. Tseng, H. W. Chang, J. Stocker et al., “A method to identify RNA A-to-I editing targets using I-specific cleavage and exon array analysis,” Molecular and Cellular Probes, vol. 27, no. 1, pp. 38–45, 2013.
- S. Farajollahi and S. Maas, “Molecular diversity through RNA editing: a balancing act,” Trends in Genetics, vol. 26, no. 5, pp. 221–230, 2010.
- C. P. Sie and M. Kuchka, “RNA editing adds flavor to complexity,” Biochemistry, vol. 76, no. 8, pp. 869–881, 2011.
- H. Wahlstedt and M. Ohman, “Site-selective versus promiscuous A-to-I editing,” Wiley Interdisciplinary Reviews, vol. 2, no. 6, pp. 761–771, 2011.
- N. Amariglio and G. Rechavi, “A-to-I RNA editing: a new regulatory mechanism of global gene expression,” Blood Cells, Molecules, and Diseases, vol. 39, no. 2, pp. 151–155, 2007.
- A. A. Zamyatnin, K. G. Lyamzaev, and R. A. Zinovkin, “A-to-I RNA editing: a contribution to diversity of the transcriptome and an organism's development,” Biochemistry, vol. 75, no. 11, pp. 1316–1323, 2010.
- S. Maas, “Posttranscriptional recoding by RNA editing,” Advances in Protein Chemistry and Structural Biology, vol. 86, pp. 193–224, 2012.
- I. G. S. Laurent 3rd, Y. A. Savva, and R. Reenan, “Enhancing non-coding RNA information content with ADAR editing,” Neuroscience Letters, vol. 466, no. 2, pp. 89–98, 2009.
- A. L. Chateigner-Boutin and I. Small, “Plant RNA editing,” RNA Biology, vol. 7, no. 2, pp. 213–219, 2010.
- B. Castandet and A. Araya, “The nucleocytoplasmic conflict, a driving force for the emergence of plant organellar RNA editing,” IUBMB Life, vol. 64, no. 2, pp. 120–125, 2012.
- S. Kwak and Y. Kawahara, “Deficient RNA editing of GluR2 and neuronal death in amyotropic lateral sclerosis,” Journal of Molecular Medicine, vol. 83, no. 2, pp. 110–120, 2005.
- S. Maas, “Gene regulation through RNA editing,” Discovery medicine, vol. 10, no. 54, pp. 379–386, 2010.
- B. Z. Tan, H. Huang, R. Lam, and T. W. Soong, “Dynamic regulation of RNA editing of ion channels and receptors in the mammalian nervous system,” Molecular Brain, vol. 2, no. 1, article 13, 2009.
- C. Orlandi, A. Barbon, and S. Barlati, “Activity regulation of adenosine deaminases acting on RNA, (ADARs),” Molecular Neurobiology, vol. 45, no. 1, pp. 61–75, 2012.
- B. L. Bass, “RNA editing by adenosine deaminases that act on RNA,” Annual Review of Biochemistry, vol. 71, pp. 817–846, 2002.
- K. Iwamoto, N. Nakatani, M. Bundo, T. Yoshikawa, and T. Kato, “Altered RNA editing of serotonin 2C receptor in a rat model of depression,” Neuroscience Research, vol. 53, no. 1, pp. 69–76, 2005.
- M. Tohda, M. Nomura, and Y. Nomura, “Molecular pathopharmacology of 5-HT2C receptors and the RNA editing in the brain,” Journal of Pharmacological Sciences, vol. 100, no. 5, pp. 427–432, 2006.
- H. A. Hundley and B. L. Bass, “ADAR editing in double-stranded UTRs and other noncoding RNA sequences,” Trends in Biochemical Sciences, vol. 35, no. 7, pp. 377–383, 2010.
- W. M. Gommans, “A-to-I editing of microRNAs: regulating the regulators?” Seminars in Cell and Developmental Biology, vol. 23, no. 3, pp. 251–257, 2012.
- M. Hogg, S. Paro, L. P. Keegan, and M. A. O'Connell, “RNA editing by mammalian ADARs,” Advances in Genetics, vol. 73, no. C, pp. 87–120, 2011.
- C. E. Hamilton, F. N. Papavasiliou, and B. R. Rosenberg, “Diverse functions for DNA and RNA editing in the immune system,” RNA Biology, vol. 7, no. 2, pp. 220–228, 2010.
- D. Hartwig, C. Schütte, J. Warnecke et al., “The large form of ADAR 1 is responsible for enhanced hepatitis delta virus RNA editing in interferon-α-stimulated host cells,” Journal of Viral Hepatitis, vol. 13, no. 3, pp. 150–157, 2006.
- R. Chen, S. D. Linnstaedt, and J. L. Casey, “RNA editing and its control in hepatitis delta virus replication,” Viruses, vol. 2, no. 1, pp. 131–146, 2010.
- R. Shtrichman, I. Germanguz, R. Mandel et al., “Altered A-to-I RNA editing in human embryogenesis,” PLoS One, vol. 7, no. 7, Article ID e41576, 2012.
- N. McCarthy, “Tumorigenesis: cut here for differentiation,” Nature Reviews Cancer, vol. 12, no. 5, p. 320, 2012.
- E. Scholzova, R. Malik, J. Sevcik, and Z. Kleibl, “RNA regulation and cancer development,” Cancer Letters, vol. 246, no. 1-2, pp. 12–23, 2007.
- B. E. Wulff and K. Nishikura, “Substitutional A-to-I RNA editing,” Wiley Interdisciplinary Reviews, vol. 1, no. 1, pp. 90–101, 2010.
- Q. Wang, “RNA editing catalyzed by ADAR1 and its function in mammalian cells,” Biochemistry, vol. 76, no. 8, pp. 900–911, 2011.
- N. Paz, E. Y. Levanon, N. Amariglio et al., “Altered adenosine-to-inosine RNA editing in human cancer,” Genome Research, vol. 17, no. 11, pp. 1586–1595, 2007.
- A. Gallo and S. Galardi, “A-to-I RNA editing and cancer: From pathology to basic science,” RNA Biology, vol. 5, no. 3, pp. 135–139, 2008.
- T. He, P. Du, and Y. Li, “dbRES: a web-oriented database for annotated RNA editing sites,” Nucleic Acids Research, vol. 35, no. 1, pp. D141–D144, 2007.
- A. Kiran and P. V. Baranov, “DARNED: a database of RNa editing in humans,” Bioinformatics, vol. 26, no. 14, Article ID btq285, pp. 1772–1776, 2010.
- A. M. Kiran, J. J. O'Mahony, K. Sanjeev, and P. V. Baranov, “Darned in 2013: inclusion of model organisms and linking with Wikipedia,” Nucleic Acids Research, vol. 41, no. D1, pp. D258–D261.
- A. Lagana, A. Paone, D. Veneziano et al., “miR-EdiTar: a database of predicted A-to-I edited miRNA target sites,” Bioinformatics, vol. 28, no. 23, pp. 3166–3168, 2012.
- E. Picardi, M. D'Antonio, D. Carrabino, T. Castrignanò, and G. Pesole, “ExpEdit: a webserver to explore human RNA editing in RNA-Seq experiments,” Bioinformatics, vol. 27, no. 9, Article ID btr117, pp. 1311–1312, 2011.
- S. C. Forster, A. M. Finkel, J. A. Gould, and P. J. Hertzog, “RNA-eXpress annotates novel transcript features in RNA-seq data,” Bioinformatics, vol. 29, no. 6, pp. 810–812, 2013.
- E. A. O'Brien, Y. Zhang, E. Wang et al., “GOBASE: an organelle genome database,” Nucleic Acids Research, vol. 37, no. 1, pp. D946–D950, 2009.
- E. Picardi, T. M. R. Regina, D. Verbitskiy, A. Brennicke, and C. Quagliariello, “REDIdb: an upgraded bioinformatics resource for organellar RNA editing sites,” Mitochondrion, vol. 11, no. 2, pp. 360–365, 2011.
- H. Lenz and V. Knoop, “PREPACT 2.0: Predicting C-to-U and U-to-C RNA Editing in organelle genome sequences with multiple references and curated RNA editing annotation,” Bioinformatics and Biology Insights, vol. 7, pp. 1–19, 2013.
- H. Wang, Z. Hou, Y. Wu, X. Ma, and X. Luo, “p150 ADAR1 isoform involved in maintenance of HeLa cell proliferation,” BMC Cancer, vol. 6, article 282, 2006.
- R. A. Steinman, Q. Yang, M. Gasparetto et al., “Deletion of the RNA-editing enzyme ADAR1 causes regression of established chronic myelogenous leukemia in mice,” International Journal of Cancer, vol. 132, no. 8, pp. 1741–1750, 2013.
- C. Cenci, R. Barzotti, F. Galeano et al., “Down-regulation of RNA editing in pediatric astrocytomas: ADAR2 editing activity inhibits cell migration and proliferation,” The Journal of Biological Chemistry, vol. 283, no. 11, pp. 7251–7260, 2008.
- F. Galeano, C. Rossetti, S. Tomaselli et al., “ADAR2-editing activity inhibits glioblastoma growth through the modulation of the CDC14B/Skp2/p21/p27 axis,” Oncogene, vol. 32, no. 8, pp. 998–1009, 2013.
- D. E. Zilberman, M. Safran, N. Paz et al., “Does RNA editing play a role in the development of urinary bladder cancer?” Urologic Oncology, vol. 29, no. 1, pp. 21–26, 2011.
- L. Chen, Y. Li, C. H. Lin et al., “Recoding RNA editing of AZIN1 predisposes to hepatocellular carcinoma,” Nature Medicine, vol. 19, no. 2, pp. 209–216, 2013.
- T. Shimokawa, M. F. Rahman, U. Tostar et al., “RNA editing of the GLI1 transcription factor modulates the output of Hedgehog signaling,” RNA Biology, vol. 10, no. 2, 2013.
- D. Dominissini, S. Moshitch-Moshkovitz, N. Amariglio, and G. Rechavi, “Adenosine-to-inosine RNA editing meets cancer,” Carcinogenesis, vol. 32, no. 11, pp. 1569–1577, 2011.
- F. Galeano, S. Tomaselli, F. Locatelli, and A. Gallo, “A-to-I RNA editing: the, "ADAR" side of human cancer,” Seminars in Cell & Developmental Biology, vol. 23, no. 3, pp. 244–250, 2012.
- E. S. Barrie, R. M. Smith, J. C. Sanford, and W. Sadee, “mRNA transcript diversity creates new opportunities for pharmacological intervention,” Molecular Pharmacology, vol. 81, no. 5, pp. 620–630, 2012.
- M. V. Morabito and R. B. Emeson, “RNA editing as a therapeutic target for CNS disorders,” Neuropsychopharmacology, vol. 34, no. 1, p. 246, 2009.
- T. D. Werry, R. Loiacono, P. M. Sexton, and A. Christopoulos, “RNA editing of the serotonin 5HT2C receptor and its effects on cell signalling, pharmacology and brain function,” Pharmacology and Therapeutics, vol. 119, no. 1, pp. 7–23, 2008.
- A. K. Streit and N. Decher, “A-to-I RNA editing modulates the pharmacology of neuronal ion channels and receptors,” Biochemistry, vol. 76, no. 8, pp. 890–899, 2011.
- J. D. Durrant and J. A. McCammon, “Towards the development of novel Trypanosoma brucei RNA editing ligase 1 inhibitors,” BMC Pharmacology, vol. 11, p. 9, 2011.
- J. D. Durrant, L. Hall, R. V. Swift, M. Landon, A. Schnaufer, and R. E. Amaro, “Novel naphthalene-based inhibitors of Trypanosoma brucei RNA editing ligase 1,” PLoS Neglected Tropical Diseases, vol. 4, no. 8, article e803, 2010.
- E. Picardi and C. Quagliariello, “EdiPy: a resource to simulate the evolution of plant mitochondrial genes under the RNA editing,” Computational Biology and Chemistry, vol. 30, no. 1, pp. 77–80, 2006.
- P. Du, L. Jia, and Y. Li, “CURE-chloroplast: a chloroplast C-to-U RNA editing predictor for seed plants,” BMC Bioinformatics, vol. 10, article 135, 2009.
- L. Cui, N. Veeraraghavan, A. Richter et al., “ChloroplastDB: the chloroplast genome database,” Nucleic acids research., vol. 34, pp. D692–D696, 2006.
- K. Yura, S. Sulaiman, Y. Hatta, M. Shionyu, and M. Go, “RESOPS: a database for analyzing the correspondence of rna editing sites to protein three-dimensional structures,” Plant and Cell Physiology, vol. 50, no. 11, pp. 1865–1873, 2009.